Overview

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.

Phase:

Phase 3

Details

Lead Sponsor:

Acorda Therapeutics

Treatments:

4-Aminopyridine